Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

Diabetic Foot Clinical Trial

Official title:

A Randomized, Open Label, Controlled, Phase 2, Multi-Center Study to Assess Safety, Tolerability and Efficacy of Adjunctive Treatment With Topically Applied MBN-101 (Pravibismane Topical Suspension) in Subjects With Moderate Diabetic Foot Infection (DFI)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05174806
• Other study ID #: MBN-101-203
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 13, 2022
• Est. completion date: March 2024

Study information

• Verified date: February 2024
• Source: Microbion Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, open label, controlled, multi-center study to assess safety, tolerability, and efficacy of adjunctive treatment with topically applied pravibismane (MBN-101) in patients with moderate diabetic foot infections. Patients will be randomized in a 2:1 ratio (MBN-101:standard of care). Topical pravibismane (MBN-101) will be applied three times per week for up to 12 weeks. All patients will receive systemic antibiotic treatment for a least a portion of that period. Randomization will be stratified by site.

Description:

This is a randomized, open label, controlled, multi-center study. Patients with diabetes mellitus (either type 1 or 2) and an infected wound of the foot with an International Working Group Diabetic Foot (IWGDF) severity rating of moderate will be eligible for the trial after meeting all inclusion criteria and none of the exclusion criteria. Patients (n = 54) will be randomized in a 2:1 ratio (MBN-101: standard of care). Randomization will be stratified by site. Patients randomized to the MBN-101 arm will be treated in an outpatient facility 3 times per week for the first 2 weeks. During each of the subsequent 10 weeks, patients will be treated once per week at the outpatient clinic and will be provided with enough MBN-101 for 2 additional days of treatment for self administration at home with or without the assistance of a caregiver. The duration between each dose should be greater than 24 hours, yet not exceed 72 hours for each of the 12 treatment weeks. Patients randomized to the standard of care arm will follow the same schedule (i.e., inclusive of wound dressing changes), though will not be treated with MBN-101. All subjects will initially receive systemic antibiotic treatment and undergo appropriate sharp debridement at baseline and then as directed by the treating physician through the 12-week treatment period, yet part of the standard of care treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 54
• Est. completion date: March 2024
• Est. primary completion date: January 19, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Inclusion Criteria:

• Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria.
• Has a skin ulcer located on or distal to the malleolus that is = 4 weeks that is clinically documented, and presents with clinical manifestations of a moderate infection (i.e. erythema extending = 2.0 cm from the wound margin), and not requiring hospitalization.
• Has received no more than 36 hours of antibiotic therapy for the moderately infected ulcer prior to enrollment or there is clinical and/or microbiological evidence of failure of antibiotic treatment for the treatment of the moderately infected ulcer.
• Has documented adequate arterial perfusion in the affected limb by biphasic or triphasic Doppler wave forms, a toe brachial index (TBI) =0.75, or an ankle brachial index (ABI) of >0.9).
• Has read and signed the Informed Consent Form (ICF) after the nature of the study has been fully explained.

Exclusion Criteria:

• Has proven or highly suspected, involvement of bone (i.e., osteomyelitis).
• Has an ulcer due to Charcot arthropathy.
• Has more than one concurrent, infected, diabetic foot wound on the study limb.
• Is unwilling or unable to attend clinic visits and keep research appointments.
• Is unwilling or unable to adhere to the systemic antibiotic treatment prescribed.
• Is unwilling or unable to adhere to proper pressure off-loading of the foot wound (when needed) from enrollment through EOS as directed by the treating physician.
• Has an untreated, uncontrolled, or poorly managed immunosuppressive and or autoimmune disorder.
• Plans to use any topical antibiotics, herbals remedies (e.g., honey), alternative medicines or antimicrobials, either directly or by dressings on their infected DFU at any time from enrollment through the EOS visit.
• Plans to receive treatment with larvae (maggots) for their infected DFU at any time from enrollment through the EOS visit.
• Plans to receive treatment with advanced cellular therapies (e.g., Platelet-derived growth factor (PDGF), Cellular Tissue Products (CTP), granulocyte colony-stimulating factor (G CSF)) for their infected DFU at any time from enrollment through the EOS visit.
• History of major medical noncompliance.
• Any condition that has required treatment with any other bismuth containing compound within 2 weeks prior to enrollment through EOS visit (i.e., Kaopectate or Pepto-Bismol, including topical applications such as Xeroform).
• Plans to receive treatment with Hyperbaric oxygen therapy (HBOT) or topical negative pressure wound therapy (NPWT) for their infected DFU at any time from enrollment through the EOS visit.
• Glycated hemoglobin >12%.
• Has a serum creatinine, ALT, AST or Alkaline Phosphatase >3 times the upper limit of the normal range of the local testing laboratory.
• End stage renal disease requiring dialysis.
• Has an absolute neutrophil count <1000.
• Has participated in an investigational trial to evaluate pharmaceuticals or biologics either concurrently or within the past 30 days.
• Will undergo a planned surgical therapy beyond standard bedside debridement or incision and drainage, to treat the DFI after enrollment.
• Has a known allergy to bismuth and/or MBN-101 excipients (methylcellulose, Tween 80 (polysorbate 80)).
• Is immunocompromised and not well-managed due to illness [human immunodeficiency virus (HIV), autoimmune disease] or organ transplant.
• Has a history of any type of cancer (excluding non-melanoma localized skin cancer or completely excised and cured carcinoma-in-situ of uterine cervix) unless the subject has been free of cancer for > 5 years.
• Developmental disability/significant psychological disorder that in the opinion of the investigator could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures.
• Active alcohol abuse (> 14 drinks per week over the last 3 months) or substance abuse (current use of cocaine, heroin, or methamphetamines) or if drug or alcohol use will interfere with visits in clinic in the opinion of the investigator.
• Has other medical condition(s) which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results.

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Foot Infection
• Infections

Intervention

Drug:
• Topical Pravibismane
Topical Pravibismane

Other:
• Standard of Care
Standard of care treatment without investigational topical pravibismane (MBN-101) or other topical antibiotics.

Locations

Country	Name	City	State
United States	Parkland Comprehensive Wound Center	Dallas	Texas
United States	Parkland Memorial Hospital	Dallas	Texas
United States	University of Texas Southwestern Medical Center University Wound Care Clinic	Dallas	Texas
United States	University of Texas Southwestern Medical Center William P. Clements Jr. University Hospital	Dallas	Texas
United States	Limb Preservation Platform, Inc.	Fresno	California
United States	Futuro Clinical Trials, LLC	McAllen	Texas
United States	Bio-X-Cell Research	San Antonio	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Microbion Corporation	CUBRC, MTEC, and US Navy

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with adverse events	Safety and tolerability	12 weeks
Secondary	Proportion of subjects with complete wound closure	Effect of MBN-101 suspension on wound healing	12 weeks
Secondary	Proportion of subjects with a clinical cure of infection	Effect of MBN-101 suspension on resolution of infection	12 weeks
Secondary	Proportion of subjects undergoing lower-extremity amputation	Effect of topical pravibismane (MBN-101) suspension on the incidence of lower level extremity amputations	12 weeks